Search

Displaying results 1221 - 1230 of 6831 in total
  1. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

  2. Drug

    Alprenolol

    go.drugbank.com/drugs/DB00866
    ApprovedWithdrawn

    Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.

    Synonyms: 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol
  3. Drug

    Inulin

    go.drugbank.com/drugs/DB00638
    ApprovedInvestigationalNutraceutical

    Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.

  4. Drug

    Simethicone

    go.drugbank.com/drugs/DB09512
    ApprovedInvestigational

    [A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308] … Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination.

    Products: Simcone-T Sugar Free Chewable Tablet 80mg
  5. Drug

    Balsalazide

    go.drugbank.com/drugs/DB01014
    Approved

    Balsalazide works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis. Mesalazine is also known as 5-aminosalicylic acid, or 5-ASA.

  6. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A2332] Due to the rarity of these T-cell malignancies, nelarabine was first granted orphan drug status and a fast-track designation by the FDA to address the unmet therapeutic needs of these cancers. … [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline.

  7. Drug

    Cinchocaine

    go.drugbank.com/drugs/DB00527
    ApprovedVet approved

    It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)

  8. Target

    E3 ubiquitin-protein ligase HUWE1

    go.drugbank.com/bio_entities/BE0016469
    TargetHumans

    Mediates HAPSTR1 degradation, but is also a required cofactor in the pathway by which HAPSTR1 governs stress signaling (PubMed:35776542). … Ubiquitinates MFN2 to negatively regulate mitochondrial fusion in response to decreased stearoylation of TFRC (PubMed:26214738).

    Synonyms: Homologous to E6AP carboxyl terminus homologous protein 9
  9. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    [A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … [A260751] Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups.

  10. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is thought to reduce symptoms through its actions on histamine receptors.